Odevixibat treatment reverses severe phenotype of PFIC in a young adult: A real-life experience beyond the genetic diagnosis
Saved in:
| Main Authors: | Claudia Mandato, Mario Masarone, Mariano Festa, Pietro Torre, Marcello Persico |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | JHEP Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555925001648 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years
by: Pietro Torre, et al.
Published: (2024-11-01) -
PECULIARITIES OF PROGRESSING FAMILY INTERLIVER CHOLESTASIA OF TYPES I AND II (PFIC I AND PFIC II)
by: A. S. Handogina
Published: (2015-04-01) -
A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease
by: Clémence Gruget, et al.
Published: (2025-04-01) -
Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis
by: Sojeong Yi, et al.
Published: (2025-01-01) -
One Family with Cholestasis: The Twisted Road to the Diagnosis of Pfic 3—Three Case Reports
by: Raluca Maria Vlad, et al.
Published: (2025-03-01)